GleamWall
中文EN

NVO NOVO NORDISK A S IFRS Annual reports only

Pharmaceutical Preparations · NYSE · SEC CIK 353278 · Reporting currency DKK · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY6.4%
TTM net income YoY1.4%
TTM EPS YoY1.8%
Revenue 3-yr CAGR20.4%
Net income 3-yr CAGR22.6%

Margins

Gross margin81.0%
Operating margin41.3%
Net margin33.1%
FCF margin19.1%
EBITDA margin46.1%

Returns

ROE60.7%
ROA20.3%
ROIC (approx.)37.9%
Asset turnover0.61x

Leverage & solvency

Liabilities / assets64.3%
Debt / equity0.67x
Current ratio0.80x
Interest coverage30.34x

Cash quality & payout

Operating cash flow / net income1.16x
Accruals ratio-3.3%
Payout ratio50.5%
Capex / revenue19.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: DKK FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue309.06B290.40B
Cost of revenue58.79B44.52B
Gross profit250.28B245.88B
R&D expense52.04B48.06B
Operating income127.66B128.34B
Interest expense4.21B1.64B
Pretax income130.54B127.19B
Income tax28.11B26.20B
Net income102.43B100.99B
EBITDA142.32B136.88B
EPS (basic)23.0622.67
EPS (diluted)23.0322.63
Weighted avg. shares (diluted)4.45B4.46B
Balance sheet
Cash & equivalents26.46B15.65B
Receivables70.86B71.95B
Inventory49.62B40.85B
Current assets172.45B161.79B
PP&E, netmay include right-of-use assets (IFRS)208.38B161.68B
Goodwill19.84B20.02B
Intangibles110.21B90.80B
Total assets542.90B465.63B
Current liabilities215.66B217.61B
Short-term debt12.02B13.11B
Long-term debt118.94B89.67B
Total debt130.96B102.79B
Total liabilities348.86B322.14B
Shareholders' equity194.05B143.49B
Net debt104.49B87.13B
Shares outstanding4.44B4.44B
Cash flow statement
Operating cash flow119.10B120.97B
Capital expenditure60.14B47.16B
Free cash flow58.96B73.80B
Investing cash flow-79.16B-128.90B
Financing cash flow-28.41B8.73B
Depreciation & amortization14.67B8.54B
Stock-based compensation1.44B2.29B
Dividends paid51.76B44.14B
Share buybacks1.39B20.18B

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, DKK, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.